blosozumab

10/01/2022 - "The inclusion criteria were: (I) randomized controlled trials (RCTs) comparing the treatment of osteoporosis with blosozumab and a placebo or without treatment, (II) studies on postmenopausal women aged over 50 years, and (III) studies providing bone mineral density data. "
10/01/2022 - "We used the keywords "osteoporosis", "decreased bone mass", and "blosozumab" to retrieve studies on the relationship between blosozumab and osteoporosis in each database. "
10/01/2022 - "Blosozumab in the treatment of postmenopausal women with osteoporosis: a systematic review and meta-analysis."
09/01/2015 - "These findings support the continued study of blosozumab as an anabolic therapy for treatment of osteoporosis."
02/01/2015 - "These results support further study of blosozumab as a potential anabolic therapy for osteoporosis."

02/01/2021 - "Novel McAb treatments achieved better therapeutic effects in the treatment of postmenopausal osteoporosis (PMO), especially blosozumab. "
08/01/2017 - "Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab."

02/01/2012 - "These data taken together demonstrated that the platelet and megakaryocyte effects in rats had a species-specific pathogenesis which likely involved LY2541546 binding of a rat-specific antigen on the surface of platelets and megakaryocytes resulting in the increased clearance of platelets and megakaryocyte hyperplasia. "

09/01/2017 - "By contrast, Dickkopf-related protein 1 (DKK1), SOST and glycogen synthase kinase 3β (GSK3β) are targets of pro-WNT signaling therapy, and anti-DKK1 (BHQ880 and DKN-01) and anti-SOST (blosozumab, BPS804 and romosozumab) monoclonal antibodies are being tested in clinical trials for cancer patients and osteoporotic post-menopausal women. "

09/01/2015 - "The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density."
02/01/2015 - "A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density."
02/01/2015 - "We report the results of a randomized, double-blind, placebo-controlled multicenter phase 2 clinical trial of blosozumab, a humanized monoclonal antibody targeted against sclerostin, in postmenopausal women with low bone mineral density (BMD). "
01/01/2019 - "Examples are included to illustrate the use of these approaches during the development of several drugs for metabolic bone diseases such as bisphosphonates, denosumab, teriparatide and sclerostin inhibitors (romosozumab and blosozumab)."